With the unveiling of clinical studies of programmed death receptor 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors, immune checkpoint inhibitor (ICI)-based immunotherapy has shown encouraging efficacy in multiple cancer types (27–29). This evidence concerns the gene PDCD1 and cancer.